(688513)"Chengdu Easton Biopharmaceuticals Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 688513 · · 12 pages · Chinese
Summary by 6ix AI
The report indicates a decline in both revenue and net profit compared to the same period last year, with significant reductions in key financial metrics. The company has emphasized its commitment to the accuracy and completeness of the report, asserting that it has not been audited. Additionally, the report highlights an increase in research and development expenditures as part of its strategic focus on innovation.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Chengdu Easton Biopharmaceuticals Co., Ltd. on 6ix
Earlier from Chengdu Easton Biopharmaceuticals
- (688513)"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Convening the Q3 2026 Performance Briefing
- (688513)"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Voluntary Disclosure of Receipt of Drug Registration Certificate for Ponatinib Tablets
- (688513)"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Vitamin K1 Injection
- Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2026
- Announcement on Closure of Certain Special Accounts for Raised Funds
Later from Chengdu Easton Biopharmaceuticals
- (688513)"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Implementation of Repurchase and Cancellation of Certain Shares under the 2024 Employee Stock Ownership Plan
- (688513)"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Voluntary Disclosure of the First Inclusion of Class 2 Modified New Drug Oxycodone and Acetaminophen Sustained-release Tablets in the National Reimbursement Drug List upon Passing National Medical Insurance Negotiation
- (688513)"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Voluntary Disclosure of Completion of First Subject Dosing in the Phase II/III Clinical Trial of EP-0226 Tablets for the Treatment of Postherpetic Neuralgia
- (688513)"Chengdu Easton Biopharmaceuticals Co., Ltd."Announcement on Progress of Tax-related Matters of a Subsidiary
- (688513)"Chengdu Easton Biopharmaceuticals Co., Ltd."Indicative Announcement on Proposal by the Controlling Shareholder, Actual Controller and Chairman to Repurchase Shares
Follow Chengdu Easton Biopharmaceuticals into a list and get an email when it puts out news.
Follow Chengdu Easton Biopharmaceuticals